SPRC Profile
SciSparc Ltd., a clinical-stage pharmaceutical company, is at the forefront of developing cannabinoid-based therapeutics targeting a range of complex medical conditions. The company focuses on harnessing cannabinoid molecules to create innovative treatments for various disorders. Its drug development pipeline features SCI-110, a compound in development for Tourette syndrome, obstructive sleep apnea, Alzheimer's disease, and associated agitation. This product is designed to leverage the therapeutic potential of cannabinoids to address these challenging conditions.
Another key development program is SCI-160, which is being explored as a treatment for pain. This drug aims to provide new options for pain management by utilizing cannabinoid-based mechanisms. Additionally, SCI-210 is under development for the treatment of autism spectrum disorder and epilepsy, reflecting the company's commitment to addressing neurodevelopmental and neurological conditions with its cannabinoid technology. The focus on these diverse therapeutic areas highlights SciSparc's strategy to address unmet medical needs through its proprietary cannabinoid-based platform.
SciSparc Ltd. has established several strategic partnerships to advance its drug development programs. It has a collaboration with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet available in soft gel capsule form. Furthermore, the company is working with the Sheba Fund for Health Services and Research to explore the potential of SCI-210 in treating status epilepticus, a severe form of epilepsy. Additionally, SciSparc has partnered with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial assessing the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation.
Originally incorporated as Therapix Biosciences Ltd., the company rebranded to SciSparc Ltd. in January 2021 to better reflect its focus on cannabinoid-based therapeutics. Headquartered in Tel Aviv-Yafo, Israel, SciSparc continues to advance its clinical programs and explore new opportunities within the cannabinoid pharmaceutical space. With a commitment to innovative drug development and strategic collaborations, SciSparc aims to make significant contributions to the treatment of complex medical conditions and enhance patient care through its specialized therapies.
|
